Natalizumab Patent Expiration
Natalizumab Large Molecule Patents
Given below is the list of large molecule patents protecting Natalizumab, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tysabri | USUS7759117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun 21, 2024
(Expired) | Biogen Inc. |
| Tysabri | USUS9096879 | Method of supplementing culture media to prevent undesirable amino acid substitutions | Jan 07, 2031 | Biogen Inc. |
| Tysabri | USUS11287423 | Assay for JC virus antibodies | Jan 11, 2031 | Biogen Inc. |
| Tysabri | USUS10119976 | Method of assessing risk of PML | May 27, 2034 | Biogen Inc. |
| Tysabri | USUS10844416 | Manganese supplementation for control of glycosylation in mammalian cell culture process | Jun 01, 2036 | Biogen Inc. |
| Tysabri | USUS8871449 | Methods and products for evaluating an immune response to a therapeutic protein | Apr 12, 2026 | Biogen Inc. |
| Tysabri | USUS9562252 | Methods of preventing and removing trisulfide bonds | May 11, 2033 | Biogen Inc. |
| Tysabri | USUS10705095 | Methods and products for evaluating an immune response to a therapeutic protein | Apr 04, 2026 | Biogen Inc. |
| Tysabri | USUS11124760 | Methods for overcoming glutamine deprivation during mammalian cell culture | Aug 27, 2035 | Biogen Inc. |
| Tysabri | USUS8809049 | Methods for producing mammalian cells | May 22, 2031 | Biogen Inc. |
| Tysabri | USUS9109015 | Method of isolating biomacromolecules using low pH and divalent cations | Aug 13, 2031 | Biogen Inc. |
| Tysabri | USUS10676772 | Control of protein glycosylation by culture medium supplementation and cell culture process parameters | Aug 19, 2034 | Biogen Inc. |
| Tysabri | USUS9790533 | Methods of preventing and removing trisulfide bonds | May 11, 2032 | Biogen Inc. |
| Tysabri | USUS11292845 | Methods of treating inflammatory and autoimmune diseases with natalizumab | Feb 28, 2027 | Biogen Inc. |
| Tysabri | USUS8318416 | Nutrient monitoring and feedback control for increased bioproduct production | Jan 20, 2031 | Biogen Inc. |
| Tysabri | USUS10444234 | Assay for JC virus antibodies | Jan 11, 2031 | Biogen Inc. |
| Tysabri | USUS8124350 | Methods and products for evaluating an immune response to a therapeutic protein | Aug 02, 2027 | Biogen Inc. |
| Tysabri | USUS9696307 | Methods for the detection of JC polyoma virus | Feb 05, 2030 | Biogen Inc. |
| Tysabri | USUS10233245 | Methods of treating inflammatory and autoimmune diseases with natalizumab | Feb 28, 2027 | Biogen Inc. |
| Tysabri | USUS11268119 | Copper supplementation for control of glycosylation in mammalian cell culture process | Feb 21, 2036 | Biogen Inc. |
| Tysabri | USUS9493567 | Methods of treating inflammatory and autoimmune diseases with natalizumab | Mar 05, 2027 | Biogen Inc. |
| Tysabri | USUS9005926 | Methods of preventing and removing trisulfide bonds | Oct 01, 2030 | Biogen Inc. |
| Tysabri | USUS9212379 | Nutrient monitoring and feedback control for increased bioproduct production | Nov 28, 2030 | Biogen Inc. |
| Tysabri | USUS11280794 | Method of assessing risk of PML | May 27, 2034 | Biogen Inc. |
| Tysabri | USUS10308706 | Methods of preventing and removing trisulfide bonds | Feb 05, 2031 | Biogen Inc. |
| Tysabri | USUS7157276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun 21, 2024
(Expired) | Biogen Inc. |
| Tysabri | USUS10590454 | Methods of preventing and removing trisulfide bonds | May 11, 2032 | Biogen Inc. |
| Tysabri | USUS9709575 | Methods and products for evaluating an immune response to a therapeutic protein | Apr 04, 2026 | Biogen Inc. |
| Tysabri | USUS9994968 | Electrochemical etching apparatus | Aug 19, 2034 | Biogen Inc. |
| Tysabri | USUS9316641 | Assay for JC virus antibodies | Jan 09, 2032 | Biogen Inc. |
| Tysabri | USUS10677803 | Method of assessing risk of PML | May 27, 2034 | Biogen Inc. |
| Tysabri | USUS10023831 | Gas delivery devices and associated systems and methods | Mar 17, 2035 | Biogen Inc. |
Natalizumab's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List